Title: Study of comparative effect of hydroxychloroquine and vildagliptin on glycaemic efficacy and HbA1c in type 2 diabetes patients who were inadequately controlled with metformin and glimepiride dual therapy
Authors: Dr Arjun Baidya, Dr Manish Kumar, Dr Shailesh Kumar Pathak, Dr Rishad Ahmed
DOI: https://dx.doi.org/10.18535/jmscr/v6i4.68
Abstract
Objective: The objective of this study is investigate the glycaemic efficacy parameters of hydroxychloroquine (HCQ) in comparison to those of vildagliptin in uncontrolled type 2 diabetes mellitus (T2DM) patients who were inadequately controlled with metformin and glimepiride dual therapy.
Methods: Uncontrolled type 2 diabetes patients with glycated haemoglobin (HbA1c) of 7.0–9.0% and on metformin up to 1000 mg/day along with glimepiride up to 2 mg/day were selected for the study. Hundredeligible patients were randomly divided into two groups. One group comprises of 50 patients whose baseline fasting plasma glucose (FPG), post prandial plasma glucose (PPPG), HbA1c were determined and the patients were put on hydroxychloroquine 400 mg per day apart from metformin 1gm /day and glimepiride 2mg/day, another group comprises of 50 patients whose baseline FPG, PPPG, HbA1c were determined and put on vildagliptin 100 mg per day apart from metformin 1gm /day and glimepiride 2mg/day. At 3 months and 6 months, levels of glycaemic parameters were compared with those at baseline.
Results: At 3 months, while similar reductions of glycated hemoglobin (HbA1c) levels were observed with these two drugs, after 24 weeks of treatment with hydroxychloroquine 400mg, metformin and glimepiride, subjects had greater reduction in FPG, PPPG and HbA1c as compared to vildagliptin, glimepiride and metformin.
Conclusion: This study showed that hydroxychloroquine can be an effective alternative to DPP4 inhibitors like vildagliptin for add on therapy to the patients who are inadequately controlled with metformin and glimepiride dual therapy.
Keywords: Glycemic efficacy, HbA1c, Hydroxychloroquine, Type2 diabetes, Vildagliptin.
References
- Abdulfatai B. Olokoba, Olusegun A. Obateru, Lateefat B. Olokoba. Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Medical Journal (2012) ; 27: 269-273.
- Chen, L.,Magliano, D. J., and Zimmet, P. Z. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nature Reviews Endocrinology, 2012; 8(4): 228-236.
- Ahmed AM. History of diabetes mellitus. Saudi Med J 2002 Apr; 23(4):373-378.
- Hage MP, Al-Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Therapeutic advances in endocrinology and metabolism. 2014 Aug 1;5(4):77-85.
- Quatraro A., Consoli G., Magno M., Caretta F., Nardozza A., Ceriello A., et al. (1990)Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus.a new job for an old drug?Ann Intern Med 112: 678–681.
- Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward MM. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. Jama. 2007 Jul 11;298(2):187-93.
- Mudaliar S. New frontiers in the management of type 2 diabetes. Indian J Med Res. 2007;125: 275-96.
- Lebovitz HE. Insulin resistance: definition and consequences. ExpClinEndocrinol Diabetes. 2001; 109 (2): 135-148.
- Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the ADA and the EAS. Diabetes Care. 2006;29(8):1963-72.
- Duckworth WC et al. Endocr Rev. 1998 Oct;19(5):608-24
- Farris W et al. ProcNatlAcadSci USA. 2003 Apr 1; 100(7):4162-7
- Iwamoto Y et al. Eur J Pharmacol. 2001 Oct 12; 428(3):381-8.
- Emami J et al. Can J PhysiolPharmacol. 1999 Feb; 77(2): 118-23.
- Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015 Oct;58(10):2336-43. doi: 10.1007/s00125-015-3689-2. Epub 2015 Jul 22.
- Pareek A, Chandurkar N, Thomas N et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin 2014; 30: 1257–1266.
- Jagnani VK, Bhattacharya NR, Satpathy SC, Hasda GC, Chakraborty S (2017) Effect of Hydroxychloroquine on Type 2 Diabetes Mellitus Unresponsive to More Than Two Oral Antidiabetic Agents.J Diabetes Metab 8: 771.